Oscar Health, Inc. (OSCR) is facing a pre-market plunge of 5.08% on Monday, following a significant 8.35% drop in the previous trading session. The continued downward pressure on the stock comes in the wake of a bearish analyst report from Barclays, which has reiterated its Sell rating on the health insurance technology company.

Barclays analyst Andrew Mok CFA maintained a Sell rating on Oscar Health, with a price target of $13.00. This reaffirmation of the negative outlook by a major financial institution has sparked investor concerns, leading to the sharp decline in Oscar Health's stock price. Analyst ratings and price targets often carry substantial weight in the market, influencing investor sentiment and trading decisions.

The persistent bearish stance from Barclays suggests ongoing challenges for Oscar Health in the competitive health insurance sector. Investors and market watchers will likely be closely monitoring the company's performance and any further analyst commentary in the coming days to gauge the potential long-term implications of this rating on Oscar Health's market position and stock valuation. As the pre-market plunge indicates, the negative sentiment surrounding the stock may continue to impact its performance in the near term.